Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 14, Issue 5, 2008, Pages 669-673

  Walkiewicz, Dorota ^a   Werlin, Steven L ^a   Fish, Daryl ^a   Scanlon, Mathew ^a   Hanaway, Patrick ^b   Kugathasan, Subra ^a,c  

^a CHILDREN S HOSPITAL OF WISCONSIN   (United States)

^b Genova Diagnostics   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Calprotectin; Children; Disease activity; IBD

Indexed keywords

CALGRANULIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CORRELATION ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FISHER EXACT TEST; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; PEDIATRICS; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; RANK SUM TEST; RELAPSE; REMISSION; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; PROGNOSIS; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 44349168884     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20376     Document Type: Article

References (38)

1. Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol. 1997;50:113-123.
2. Steinbakk M, Naess-Andresen CF, Lingaas E, et al. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet. 1990;336:763-765.
3. Sohnle PG, Collins-Lech C, Wiessner JH. Antimicrobial activity of an abundant calcium-binding protein in the cytoplasm of human neutrophils. J Infect Dis. 1991;163:187-192.
4. Yui S, Mikami M, Yamazaki M. Induction of apoptotic cell death in mouse lymphoma and human leukemia cell lines by a calcium-binding protein complex, calprotectin, derived from inflammatory peritoneal exudates cells. J Leukoc Biol. 1995;58:650-658.
5. Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol Pharm Bull. 2003;26:753-760.
6. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999;34:50-54.
7. Roseth AG. Determination of faecal calprotectin, a novel marker of organic gastrointestinal disorders. Dig Liver Dis. 2003;35:607-609.
8. Berstad A, Arslan G, Folvik G. Relationship between intestinal permeability and calprotectin concentration in gut lavage fluid. Scand J Gastroenterol. 2000;35:64-69.
9. Fagerhol MK. Calprotectin, a faecal marker of organic gastrointestinal abnormality. Lancet. 2000;356:1783-1784.
10. Aadland E, Fagerhol MK. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol. 2002;14:823-825.
11. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 2000;47:506-513.
12. Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol. 2001;7:460-465.
13. Berni Canani R, Rapacciullo L, Romano MT, et al. Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. Digest Liver Dis. 2004;36:467-470.
14. Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;33:14-22.
15. Gaya DR, Lyon TD, Duncan A, et al. Faecal calprotectin in the assessment of Crohn's disease activity. Q J Med. 2005;98:435-441.
16. Roseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 1997;58:176-180.
17. Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;32:171-177.
18. Olafsdottir E, Aksnes L, Fluge G, et al. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr. 2002;91:45-50.
19. Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology. 2002;123:450-460.
20. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005;54:364-368.
21. Hanaway P, Roseth A. Inflammatory biomarkers predict relapse in IBD. Gut. 2005;54:1346-1347.
22. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15-22.
23. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004;39:1017-1020.
24. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
25. Reed JF 3rd, Faust LA, Rosen L. Assessment of disease activity in a registry of Crohn's disease patients in eastern Pennsylvania. Z Gastroenterol. 1991;29:378-382.
26. Jorgensen LG, Fredholm L, Hyltoft Petersen P, et al. How accurate are clinical activity indices for scoring of disease activity in inflammatory bowel disease (IBD)? Clin Chem Lab Med. 2005;43:403-411.
27. Hyams JS, Mandel F, Ferry GD, et al. Relationship of common laboratory parameters to the activity of Crohn's disease in children. J Pediatr Gastroenterol Nutr. 1992;14:216-212
28. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
29. Cuffari C, Theoret Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut. 1996;39:401-406.
30. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of acute ulcerative colitis: results of a controlled trial. Am J Gastroenterol. 1993;88:1188-1197.
31. Ton H, Brandsnes, Dale S, et al. Improved assay for fecal calprotectin. Clin Chim Acta. 2000;292:41-54.
32. Costa F, Mumolo MG, Bellini M, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003;35:642-647.
33. Tibble JA, Bjarnason I. Fecal calprotectin as an index of intestinal inflammation. Drugs Today (Barc). 2001;37:85-96.
34. Poullis A, Foster R, Mendall MA, et al. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol. 2003;18:756-762.
35. Roseth AG, Kristinsson J, Fagerhol MK, et al. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol. 1993;28:1073-1076.
36. Poullis A, Foster R, Shetty A, et al. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2004;13:279-284.
37. Fagerberg UL, Loof L, Merzoug RD, et al. Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr. 2003;37:468-472.
38. Poullis A, Irwin AG, Dearing M, et al. Repeat planar white cell scanning to monitor short-term therapy of active inflammatory bowel disease: a methodological study and comparison with clinical scores and novel inflammatory markers. Eur J Gastroenterol Hepatol. 2006;18:607-614.